Reuters -- Sihuan Pharmaceutical Holdings Group Ltd, China’s largest cardio-cerebral vascular drugmaker, plans to raise $600-700 million from a Hong Kong initial public offering this month, sources familiar with the matter told Reuters on Monday, joining a flurry of stock offerings in the city in recent months.
